Back to News
Market Impact: 0.35
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Helus Pharma expects pivotal Phase III data for HLP003 in adjunctive major depressive disorder in Q4. The readout is a key near-term catalyst for the company’s mental-health treatment pipeline and could materially affect the stock depending on efficacy and safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
HELP0.45
More News
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- Leonardo raises 2026 order guidance after strong 9-mth performance
- HelloFresh Q3 core profit tops forecasts as marketing cuts hit orders
- Microsoft declines Nscale Texas expansion ahead of $35 bln IPO - report
- Hensoldt Q3 adjusted EBITDA beats forecasts, 2026 sales target raised